Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)

Cristiana Sessa, Massimo Zucchetti, Michele Ghielmini, Jean Bauer, Maurizio D'Incalci, Jolanda De Jong, Huguette Naegele, Simona Rossi, Maria Adele Pacciarini, Letizia Domenigoni, Franco Cavalli

Research output: Contribution to journalArticle

Abstract

Purpose: The methoxymorpholinyl doxorubicin analogue PNU 152243 was brought into clinical studies because of preclinical observations of its non- cross-resistance in mdr tumor cells, dose-limiting neutropenia, lack of cardiotoxicity, and antitumor activity after oral administration. Methods: PNU 152243 was given orally every 4 weeks to 21 adults with a variety of solid tumors at doses ranging from 59 to 940 μg/m2. Antiemetic prophylaxis with 5-HT3 antagonists and steroids, given i.v. on day 1 and orally on days 2-8, was required beginning with the dose of 118 μg/m2. The plasma pharmacokinetics of PNU 152243 were determined by an HPLC method with fluorescence detection. The in vitro myelotoxic effects on granulocyte macrophage-colony forming cells (GM-CFC) of the plasma from 11 patients, obtained 4 and 6 h after treatment at all dose levels, were also assessed. Results: Neutropenia was the main hematologic toxic effect and the maximum tolerated dose (MTD) for myelotoxicity was 940 μg/m2, with neutropenia grade 3-4 in two of three patients: Dose-dependent nausea and vomiting were dose-limiting and the MTD for gastrointestinal toxicity was fixed at 820 μg/m2, with grade 4 vomiting in one of two patients. Other frequent toxic effects were diarrhea and fatigue. Peak levels of PNU 152243 were achieved 4 h after dosing. Dose-dependent Cmax and AUCExp, and significant interpatient variability of the main pharmacokinetic parameters were found. Very low levels of the 13-dihydrometabolite PNU 155051 were detected only at the highest doses. The hematotoxicity tests showed a

Original languageEnglish
Pages (from-to)403-410
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume44
Issue number5
DOIs
Publication statusPublished - 1999

Fingerprint

Pharmacokinetics
Poisons
Neutropenia
Tumors
Maximum Tolerated Dose
Pharmacology
Serotonin 5-HT3 Receptor Antagonists
Plasmas
Vomiting
Antiemetics
Macrophages
Toxicity
Fluorescence
Steroids
Cells
Fatigue of materials
Plasma Cells
Granulocytes
Nausea
Fatigue

Keywords

  • Anthracycline analogs
  • Hematotoxicology
  • Methoxymorpholinyl doxorubicin
  • Oral chemotherapy
  • Phase I

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). / Sessa, Cristiana; Zucchetti, Massimo; Ghielmini, Michele; Bauer, Jean; D'Incalci, Maurizio; De Jong, Jolanda; Naegele, Huguette; Rossi, Simona; Pacciarini, Maria Adele; Domenigoni, Letizia; Cavalli, Franco.

In: Cancer Chemotherapy and Pharmacology, Vol. 44, No. 5, 1999, p. 403-410.

Research output: Contribution to journalArticle

Sessa, C, Zucchetti, M, Ghielmini, M, Bauer, J, D'Incalci, M, De Jong, J, Naegele, H, Rossi, S, Pacciarini, MA, Domenigoni, L & Cavalli, F 1999, 'Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)', Cancer Chemotherapy and Pharmacology, vol. 44, no. 5, pp. 403-410. https://doi.org/10.1007/s002800050996
Sessa, Cristiana ; Zucchetti, Massimo ; Ghielmini, Michele ; Bauer, Jean ; D'Incalci, Maurizio ; De Jong, Jolanda ; Naegele, Huguette ; Rossi, Simona ; Pacciarini, Maria Adele ; Domenigoni, Letizia ; Cavalli, Franco. / Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). In: Cancer Chemotherapy and Pharmacology. 1999 ; Vol. 44, No. 5. pp. 403-410.
@article{a9ce3ba730cb468db20616b6acc40cb4,
title = "Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)",
abstract = "Purpose: The methoxymorpholinyl doxorubicin analogue PNU 152243 was brought into clinical studies because of preclinical observations of its non- cross-resistance in mdr tumor cells, dose-limiting neutropenia, lack of cardiotoxicity, and antitumor activity after oral administration. Methods: PNU 152243 was given orally every 4 weeks to 21 adults with a variety of solid tumors at doses ranging from 59 to 940 μg/m2. Antiemetic prophylaxis with 5-HT3 antagonists and steroids, given i.v. on day 1 and orally on days 2-8, was required beginning with the dose of 118 μg/m2. The plasma pharmacokinetics of PNU 152243 were determined by an HPLC method with fluorescence detection. The in vitro myelotoxic effects on granulocyte macrophage-colony forming cells (GM-CFC) of the plasma from 11 patients, obtained 4 and 6 h after treatment at all dose levels, were also assessed. Results: Neutropenia was the main hematologic toxic effect and the maximum tolerated dose (MTD) for myelotoxicity was 940 μg/m2, with neutropenia grade 3-4 in two of three patients: Dose-dependent nausea and vomiting were dose-limiting and the MTD for gastrointestinal toxicity was fixed at 820 μg/m2, with grade 4 vomiting in one of two patients. Other frequent toxic effects were diarrhea and fatigue. Peak levels of PNU 152243 were achieved 4 h after dosing. Dose-dependent Cmax and AUCExp, and significant interpatient variability of the main pharmacokinetic parameters were found. Very low levels of the 13-dihydrometabolite PNU 155051 were detected only at the highest doses. The hematotoxicity tests showed a",
keywords = "Anthracycline analogs, Hematotoxicology, Methoxymorpholinyl doxorubicin, Oral chemotherapy, Phase I",
author = "Cristiana Sessa and Massimo Zucchetti and Michele Ghielmini and Jean Bauer and Maurizio D'Incalci and {De Jong}, Jolanda and Huguette Naegele and Simona Rossi and Pacciarini, {Maria Adele} and Letizia Domenigoni and Franco Cavalli",
year = "1999",
doi = "10.1007/s002800050996",
language = "English",
volume = "44",
pages = "403--410",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)

AU - Sessa, Cristiana

AU - Zucchetti, Massimo

AU - Ghielmini, Michele

AU - Bauer, Jean

AU - D'Incalci, Maurizio

AU - De Jong, Jolanda

AU - Naegele, Huguette

AU - Rossi, Simona

AU - Pacciarini, Maria Adele

AU - Domenigoni, Letizia

AU - Cavalli, Franco

PY - 1999

Y1 - 1999

N2 - Purpose: The methoxymorpholinyl doxorubicin analogue PNU 152243 was brought into clinical studies because of preclinical observations of its non- cross-resistance in mdr tumor cells, dose-limiting neutropenia, lack of cardiotoxicity, and antitumor activity after oral administration. Methods: PNU 152243 was given orally every 4 weeks to 21 adults with a variety of solid tumors at doses ranging from 59 to 940 μg/m2. Antiemetic prophylaxis with 5-HT3 antagonists and steroids, given i.v. on day 1 and orally on days 2-8, was required beginning with the dose of 118 μg/m2. The plasma pharmacokinetics of PNU 152243 were determined by an HPLC method with fluorescence detection. The in vitro myelotoxic effects on granulocyte macrophage-colony forming cells (GM-CFC) of the plasma from 11 patients, obtained 4 and 6 h after treatment at all dose levels, were also assessed. Results: Neutropenia was the main hematologic toxic effect and the maximum tolerated dose (MTD) for myelotoxicity was 940 μg/m2, with neutropenia grade 3-4 in two of three patients: Dose-dependent nausea and vomiting were dose-limiting and the MTD for gastrointestinal toxicity was fixed at 820 μg/m2, with grade 4 vomiting in one of two patients. Other frequent toxic effects were diarrhea and fatigue. Peak levels of PNU 152243 were achieved 4 h after dosing. Dose-dependent Cmax and AUCExp, and significant interpatient variability of the main pharmacokinetic parameters were found. Very low levels of the 13-dihydrometabolite PNU 155051 were detected only at the highest doses. The hematotoxicity tests showed a

AB - Purpose: The methoxymorpholinyl doxorubicin analogue PNU 152243 was brought into clinical studies because of preclinical observations of its non- cross-resistance in mdr tumor cells, dose-limiting neutropenia, lack of cardiotoxicity, and antitumor activity after oral administration. Methods: PNU 152243 was given orally every 4 weeks to 21 adults with a variety of solid tumors at doses ranging from 59 to 940 μg/m2. Antiemetic prophylaxis with 5-HT3 antagonists and steroids, given i.v. on day 1 and orally on days 2-8, was required beginning with the dose of 118 μg/m2. The plasma pharmacokinetics of PNU 152243 were determined by an HPLC method with fluorescence detection. The in vitro myelotoxic effects on granulocyte macrophage-colony forming cells (GM-CFC) of the plasma from 11 patients, obtained 4 and 6 h after treatment at all dose levels, were also assessed. Results: Neutropenia was the main hematologic toxic effect and the maximum tolerated dose (MTD) for myelotoxicity was 940 μg/m2, with neutropenia grade 3-4 in two of three patients: Dose-dependent nausea and vomiting were dose-limiting and the MTD for gastrointestinal toxicity was fixed at 820 μg/m2, with grade 4 vomiting in one of two patients. Other frequent toxic effects were diarrhea and fatigue. Peak levels of PNU 152243 were achieved 4 h after dosing. Dose-dependent Cmax and AUCExp, and significant interpatient variability of the main pharmacokinetic parameters were found. Very low levels of the 13-dihydrometabolite PNU 155051 were detected only at the highest doses. The hematotoxicity tests showed a

KW - Anthracycline analogs

KW - Hematotoxicology

KW - Methoxymorpholinyl doxorubicin

KW - Oral chemotherapy

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0032834824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032834824&partnerID=8YFLogxK

U2 - 10.1007/s002800050996

DO - 10.1007/s002800050996

M3 - Article

C2 - 10501914

AN - SCOPUS:0032834824

VL - 44

SP - 403

EP - 410

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -